Assessing risk in liver transplantation: Special reference to the significance of a positive cytotoxic crossmatch

Annals of Surgery

Volumn 224, Issue 2, 1996, Pages 168-177

  Doyle, Howard R ^a,c   Marino, Ignazio R ^b,c   Morelli, Franca ^b   Doria, Cataldo ^b   Aldrighetti, Luca ^b   McMichael, John ^b   Martell, Joan ^b   Gayowski, Timothy ^b,c   Starzl, Thomas E ^b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CROSS REACTION; CYTOTOXICITY; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; CONFIDENCE INTERVALS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 0029784082     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199608000-00009     Document Type: Article

References (60)

1. Terasaki PI, Marchioro TL, Starzl TE. Sero-typing of human lymphocyte antigens: preliminary trials on long-term kidney homo-graft survivors. In: Russell PS, Winn HJ, eds. Histocompatibility Testing. Washington DC: National Academy of Science Research Council; 1965:83-96.
2. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2:662-665.
3. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739.
4. Starzl TE, Ishikawa M, Putnam CW, et al. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc 1974; 6:129-139.
5. Starzl TE, Koep LJ, Halgrimson CG, et al. Fifteen years of clinical liver transplantation. Gastroenterology 1979; 77:375-388.
6. Iwatsuki S, Iwaki Y, Kano T, et al. Successful liver transplantation from crossmatch-positive donors. Transplant Proc 1981; 13:286-288.
7. Gordon RD, Fung JJ, Markus B, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100:705-715.
8. Donaldson PT, Alexander GJM, O'Grady J, et al. Evidence for an immune response to HLA class I antigens in the vanishing bile duct syndrome after liver transplantation. Lancet 1987; 1:945-948.
9. Hanto DW, Snover DC, Sibley RK, et al. Hyperacute rejection of a human orthotopic liver allograft in a presensitized recipient. Clin Transpl 1987; 1:304-310.
10. Starzl TE, Demetris AJ, Todo S, et al. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin Transpl 1989; 3:37-45.
11. Takaya S, Bronsther O, Iwaki Y, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53:400-406.
12. Demetris AJ, Nakamura K, Yagihashi A, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 163:671-681.
13. Katz SM, Kimball PM, Ozaki C, et al. Positive pretransplant crossmatches predict early graft loss in liver allograft recipients. Transplantation 1994; 57:616-620.
14. Nikaein A, Backman L, Jennings L, et al. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation 1994; 58:786-792.
15. Takaya S, Iwaki Y, Starzl TE. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. Transplantation 1992; 54:927-929.
16. Lobo PI, Spencer C, Douglas MT, et al. The lack of long-term detrimental effects on liver allografts caused by donor-specific anti-HLA antibodies. Transplantation 1993; 55:1063-1066.
17. Marino IR, Doyle HR, Aldrighetti L, et al. Effect of donor age and sex on the outcome of liver transplantation. Hepatology 1995; 22:1754-1762.
18. Pirofsky B, Rosner ER. DTT test: a new method to differentiate IgM and IgG erythrocyte antibodies. Vox Sang 1974; 27:480-488.
19. Tellis VA, Matas AJ, Senitzer D, et al. Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody. Transplantation 1989; 47:127-129.
20. Roy R, Belles-Isles M, Pare M, et al. The importance of serum dithiothreitol treatment in crossmatching selection of presensitized kidney transplant recipients. Transplantation 1990; 50:532-534.
21. The ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655.
22. Starzl TE, Demetris AJ. Liver Transplantation. A 31-Year Perspective. Chicago: Year Book Medical Publishers, Inc; 1990.
23. Amos DB, Bashir H, Boyle W, et al. A simple micro cytotoxicity test. Transplantation 1969; 7:220-223.
24. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. New York: John Wiley and Sons; 1987:275-277.
25. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
27. Wittwer CT, Bristow MR, Gilbert EM, et al. OKT3 therapy as a cause of high panel-reactive antibodies in serum using standard microcytotoxicity techniques. Transplantation 1988; 45:832-834.
28. Ratner LE, Phelan D, Brunt EM, et al. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 1993; 55:814-819.
29. Gordon RD, Iwatsuki S, Esquivel CO, et al. Liver transplantation across ABO blood groups. Surgery 1986; 100:342-348.
30. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across the ABO blood group barriers. Am J Pathol 1988; 132:489-502.
31. Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990; 336:519-523.
32. Marino IR, Weber T, Kang YG, et al. HLA alloimmunization and blood requirements in orthotopic liver transplantation. Transplant Proc 1989; 21:789-791.
33. Avolio AW, Agnes S, Magalini SC, et al. Importance of donor blood chemistry data (AST, serum sodium) in predicting liver transplant outcome. Transplant Proc 1991; 23:2451-2452.
34. Gonzalez FX, Rimola A, Grande L, et al. Predictive factors of early postoperative graft function in human liver transplantation. Hepatology 1994; 20:565-573.
35. Starzl TE, Putnam CW. Experience in Hepatic Transplantation. Philadelphia: WB Saunders; 1969.
36. Tepperman L, Podesta L, Mieles L, Starzl TE. The successful use of older donors for liver transplantation (letter). JAMA 1989; 262:2837.
37. Wall WJ, Mimeault R, Grant DR, Bloch M. The use of older donor livers for hepatic transplantation. Transplantation 1990; 49:377-381.
38. Alexander JW, Vaughn WK. The use of "marginal" donors for organ transplantation. The influence of donor age on outcome. Transplantation 1991; 51:135-141.
39. Popper H. Aging and the liver. In: Popper H, Schaffner F, eds. Progress in Liver Disease. Volume VIII. New York: Grune & Stratton; 1986:659-683.
40. Marino IR, Doyle HR, Doria C, et al. Outcome of liver transplantation using donors 60 to 79 years of age. Transplant Proc 1995; 27:1184-1185.
41. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation - A multivariate analysis. Transplantation 1993; 55:807-813.
42. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20:829-838.
43. Furukawa H, Todo S, Imventarza O, et al. Effect of cold ischemia time on the early outcome of human hepatic allografts preserved with UW solution. Transplantation 1991; 51:1000-1004.
44. Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 1992; 16:49-53.
45. Bronsther O, Fung JJ, Tzakis A, et al. Prioritization and organ distribution for liver transplantation. JAMA 1994; 271:140-143.
46. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2:1000-1004.
47. Fung JJ, Abu-Elmagd K, Gordon R, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991; 23:2977-2983.
48. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with primary orthotopic liver transplantation with FK506 immunosuppression. Ann Surg 1994; 220:297-309.
49. McDiarmid SV, Klintmalm GB, Busuttil RW. FK506 conversion for intractable rejection of the liver allograft. Transpl Int 1993; 6:305-312.
50. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344:423-428.
51. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation 1995; 59:31-40.
52. Valdivia LA, Fung JJ, Demetris AJ, et al. Donor species complement after liver xenotransplantation. The mechanism of protection from hyperacute rejection. Transplantation 1994; 57:918-922.
53. Engelfriet CP, van der Berg-Loonen PM, de Lange GG. Screening for HLA sera. In: Ferrone S, Solheim BG, eds. HLA Typing: Methodology and Clinical Aspects. Boca Raton: CRC Press; 1982:1:57-61.
54. Johnson AH, Rossen RD, Butler TW. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens 1972; 2:215-226.
55. Johnson A, Hallman J, Alijani MR, et al. A prospective study of the clinical relevance of the current serum antiglobulin augmented T cell crossmatch in renal transplant recipients. Transplant Proc 1987; 19:792-793.
56. Kerman RH, Kimball PM, Van Buren CT, et al. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation 1991; 51:316-320.
57. Ogura K, Koyama H, Takemoto S, et al. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24:1465.
58. Cox DR, Oakes D. Analysis of Survival Data. New York: Chapman and Hall; 1984.
59. Gore SM, Pocock S, Kerr GR. Regression models and non-proportional hazards in the analysis of breast cancer survival. Appl Statistics 1984; 33:176-195.
60. Hess KR. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med 1994; 13:1045-1062.